Anatomic pathology refers to the gross and microscopic examination of organs, tissues, cells and bodily fluids. It plays a pivotal role in the diagnosis and prognosis of various diseases such as cancer which requires detailed tissue evaluation. Advancements in digital pathology and integration of artificial intelligence have streamlined workflow processes and increased diagnostic efficiency.
Market key trends:
One of the key trends driving the anatomic pathology market growth is increasing adoption of digital pathology solutions. Digital pathology involves converting glass slides into whole slide images that can be viewed, managed, shared and analyzed on digital screens instead of conventional microscope. This allows remote consultation, multi-user access and application of artificial intelligence for precision diagnosis. Many leading players are focusing on development of advanced whole slide imaging systems, virtual microscopy platforms and image analysis software with integrated AI tools. For instance, Definiens’ Tissue Phenomics suite uses artificial intelligence and machine learning algorithms to analyze digitized tissue slides and identify cancer patterns. Such technologically advanced solutions are rapidly being adopted by healthcare organizations to make anatomical pathology more efficient, cost-effective and collaborative.
The global Anatomic Pathology Market Growth is estimated to be valued at US$ 30.16 Bn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Threat of new entrants: The anatomic pathology market demands large capital investments to establish a high quality pathology laboratory with advanced equipment and skilled pathologists. This poses significant barriers for new companies.
Bargaining power of buyers: Individual consumers have little bargaining power in this market as pathological tests are typically recommended by physicians. However, large hospitals and healthcare organizations can negotiate lower prices from suppliers.
Bargaining power of suppliers: A few large multinational corporations dominate the supply of advanced diagnostic equipment and technological solutions. This enables them to influence pricing in the market.
Threat of new substitutes: There exist no viable substitute for anatomic pathology diagnostics currently. New diagnostic tests utilizing emerging technologies may provide alternatives in the future.
Competitive rivalry: The market is highly competitive with some consolidation occurring among major players.
Strength: Presence of advanced automated diagnostic solutions and technological expertise of major players. Growing adoption of digital and AI-powered solutions for improved diagnostic accuracy.
Weakness: Shortage of trained pathologists in some regions poses challenges. High investment needs for regular equipment upgrades.
Opportunity: Rising cancer incidence worldwide is boosting demand for pathology services. Growing medical tourism in developing nations.
Threats: Stringent regulatory guidelines increase compliance costs. Reimbursement issues in some countries hamper market growth.
The global anatomic pathology market is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing prevalence of chronic diseases. Cancer diagnosis accounts for a major share of the market currently.
Regional analysis North America currently dominates the market and is expected to continue its lead position during the forecast period. This can be attributed to well-established healthcare systems, presence of major market players, and rising number of diagnoses. Asia Pacific is anticipated to exhibit the fastest CAGR owing to growing medical tourism, rising healthcare infrastructure and increasing awareness among populations.
Key players operating in the anatomic pathology market are Danaher PHC Holdings CorporationQuest Diagnostics IncorporatedLaboratory Corporation of America HoldingsF. Hoffmann-La Roche AGAgilent Technologies, Inc.Cardinal HealthSakura Finetek USA, Inc.NeoGenomics Laboratories, Inc.BioGenexBio SB. These players are focusing on strategic acquisitions and new product launches to consolidate their market shares.